SUBSCRIBE
SUBSCRIBE

Lori Ellis

Head of Insights

Lori is the head of insights at BioSpace. She analyzes and comments on industry trends for BioSpace and clients. She creates engaging content for clients to support their marketing objectives. She has been part of an award-winning marketing team and has won a Muse Creative award, a Vega award and several Adobe awards in collaborative team projects for her audio narration work. Her experience in the television/film and audio industries benefits both BioSpace and partners through her moderation and hosting of live and virtual events. While she has covered all elements of the drug development process, her primary focuses are women’s health issues, the economic climate, and the ever-evolving impact of technology – specifically artificial intelligence – on the pharmaceutical industry.

Policy
The gap is where the pain is: Drug pricing and patient costs
This episode explores the drug pricing gap between consumer experience and industry norms. Join Lori and our KOLs as we explore the drivers of healthcare costs, the CBO, rebates, and overall spend in this new series.
February 29, 2024
 · 
1 min read
 · 
Lori Ellis
LGBTQIA-friendly clinical trial and data collage
Drug Development
We Don’t Know What We Don’t Know: LGBTQIA+ Patient Data and the Struggle for Inclusivity
With over 20% of people born between 1997 and 2003 identifying as a sexual and gender minority, moderated panels at SCOPE 2024 discuss the need to engage this community in clinical trials.
February 21, 2024
 · 
7 min read
 · 
Lori Ellis
Drug Delivery
Iovance wins with Amtagvi and the ADC train chugs on
This week Lori, Greg and Tyler discuss the ⁠Accelerated Approval of Amtagvi⁠, the first one-time cell therapy for solid tumors and the first TIL therapy; the ⁠FTC and HHS probe⁠ into generic drug shortages and some recent ADC-focused raises from ⁠ProfoundBio⁠ and ⁠Firefly Bio⁠.
February 20, 2024
 · 
1 min read
 · 
Lori Ellis
Pictured: "Politics, Patients, and Pharma"/Nicole
Policy
The IRA: A Catalyst for Societal Change
Politics aside, both the government and the pharmaceutical industry want to bring affordable effective therapies to patients. Implementation is the obstacle. Working together is the only way to modify the IRA to do what it intends to do: benefit patients.
February 6, 2024
 · 
7 min read
 · 
Lori Ellis
Drug Development
Keep calm and CAR-T on?
Lori, Greg and Tyler discuss last week’s ⁠call for a class-wide box warning⁠ on all commercial CAR T therapies, while investigations are ongoing into ⁠cases of secondary malignancies⁠. How do we approach this ⁠balancing act⁠ of treatment and side effects?
January 31, 2024
 · 
1 min read
 · 
Lori Ellis
Deals
Grab an umbrella, it’s raining ⁠IPOs⁠!
This week, Lori, Greg and Tyler discuss the first ⁠surge of IPO activity⁠ this year plus gene therapy pricing,
January 23, 2024
 · 
1 min read
 · 
Lori Ellis
Washington DC hi-tech smart city background. 3D rendering.
Business
Pricing, Politics and AI To Take Center Stage in 2024
As with any new year, 2024 presents new possibilities; though new and existing challenges are also poised to shape its trajectory. BioSpace reflects on the recent JP Morgan Healthcare Conference and future outlook with key opinion leaders who share their thoughts on the economic climate.
January 22, 2024
 · 
9 min read
 · 
Lori Ellis
Drug Development
Optimistic, but for how long? Our big takeaways from #JPM2024
The team comes together to discuss the dominant themes of what was an incredibly busy week of events in San Francisco during JPM 2024.
January 17, 2024
 · 
1 min read
 · 
Lori Ellis
Deals
Listen: JPM2024 Day 3 Highlights
The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 3 at JPM2024.
January 10, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
Listen: JPM2024 Day 2 Highlights
The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 2 at JPM2024.
January 9, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
Every move you make: Biopharma industry under heavy scrutiny
On this episode of the Weekly: Biden administration puts pressure on the biopharma industry; renewed interest in psychedelics after MindMed announces LSD-based candidate meets primary endpoint; bluebird changes its tune.
December 20, 2023
 · 
1 min read
 · 
Lori Ellis
FDA
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
This week, we discuss the two major FDA approvals for sickle cell from Vertex/CRISPR and bluebird bio; Axcella and the future of long-covid treatments, Vanda’s $100m purchase and AI regulatory developments in Europe.
December 13, 2023
 · 
1 min read
 · 
Lori Ellis
Deals
Deals, Dupixent and GLP-1 drug shortages
This week on The Weekly we talk struggles with ⁠GLP-1 drug shortages⁠ and what that might mean for Novo and Lilly competitors; Regeneron and Sanofi positive results for ⁠⁠⁠Dupixent⁠⁠⁠ in COPD. Plus, Merck ⁠buys Caraway⁠, Beigene’s ⁠deal⁠ with Ensem, ⁠ups⁠ and ⁠downs⁠ for Flagship.
November 29, 2023
 · 
1 min read
 · 
Lori Ellis
Drug Development
First ever CRISPR gene therapy approval: What happens next?
CRISPR gene-editing has had its first ever approval in the UK. Will the FDA follow suit? What can patients expect the price tag to be?
November 21, 2023
 · 
1 min read
 · 
Greg Slabodkin
Image Credit: Nicole Bean for BioSpace
Policy
White House and Congress Propose AI Legislation as FDA Continues to Act as AI Regulatory Gatekeeper
Both the White House and Congress have proposed legislation for the appropriate use of AI while the FDA continues to serve as the gatekeeper for patient privacy and safety.
November 21, 2023
 · 
7 min read
 · 
Lori Ellis
Load More